Home/Pipeline/LSAM-DTX

LSAM-DTX

Solid Tumors

Phase 2Active

Key Facts

Indication

Solid Tumors

Phase

Phase 2

Status

Active

Company

NanOlogy

About NanOlogy

NanOlogy is pioneering a novel intratumoral drug delivery platform to improve outcomes in solid tumors. Its proprietary Purcision™ technology creates excipient-free, large surface area microparticles (LSAMs) that act as a local drug depot, aiming to enhance tumoricidal effect and immunomodulation while drastically reducing systemic toxicity. With lead assets LSAM-PTX and LSAM-DTX having completed initial clinical trials, the company is positioned to address a significant unmet need across the spectrum of local and metastatic disease. The leadership team combines deep oncology drug development and commercial experience.

View full company profile

Therapeutic Areas

Oncology Solid Tumors

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed